Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review
Open Access
- 1 January 2015
- journal article
- review article
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 8, 13-19
Abstract
Type 2 diabetes mellitus (T2D) is a growing healthcare burden primarily due to long-term complications. Strict glycemic control helps in preventing complications, and early introduction of insulin may be more cost-effective than maintaining patients on multiple oral agents. This is an expert opinion review based on English peer-reviewed articles (2000–2012) to discuss the health economic consequences of T2D treatment intensification. T2D costs are driven by inpatient care for treatment of diabetes complications (40%–60% of total cost), with drug therapy for glycemic control representing 18% of the total cost. Insulin therapy provides the most improved glycemic control and reduction of complications, although hypoglycemia and weight gain may occur. Early treatment intensification with insulin analogs in patients with poor glycemic control appears to be cost-effective and improves clinical outcomes. Key Messages: • Type 2 diabetes mellitus is a growing burden on healthcare services. • Despite the high cost of drug therapy versus diet and lifestyle interventions, treatment intensification with insulin analog therapy is a cost-effective strategy for improving clinical outcomes in patients with poor glycemic control.Keywords
This publication has 72 references indexed in Scilit:
- Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]BMC Family Practice, 2012
- Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysisDiabetes Research and Clinical Practice, 2009
- The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling studyBMC Endocrine Disorders, 2009
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009
- The Impact of Obesity on Cardiovascular Disease Risk Factors and Subclinical Vascular DiseaseArchives of internal medicine (1960), 2008
- Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real‐Life Effectiveness and Care Patterns of Diabetes Management (RECAP‐DM) studyDiabetes, Obesity and Metabolism, 2008
- Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysisBMJ, 2008
- Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trialBMJ, 2008
- Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 DiabetesDiabetes Care, 2007
- Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?BMJ, 2006